

ABBREVIATIONS

| | |
|-----------|---|
| 5-FU | 5 fluorouracil |
| AE | Adverse event |
| ALAT | Alanine aminotransferase |
| ALP | Alkaline phosphatase |
| ASAT | Aspartate transaminase |
| AT | Austria |
| BE | Belgium |
| BPM | Beats per minute |
| CI | Confidence interval |
| CR | Complete response |
| CRA | Clinical research associate |
| CRO | Clinical research organisation |
| CT | Computerized tomography |
| DNA | Deoxyribonucleic acid |
| ECOG PS | Eastern cooperative oncology group performance status |
| EEA | European economic area |
| ES | Spain |
| ESMO | European Society for Medical Oncology |
| FOLFIRI | 5-fluorouracil + Leucovorin + Irinotecan |
| GI | Gastrointestinal |
| HU | Hungary |
| ICF | Informed consent form |
| IDMC | Independent data monitoring committee |
| ITT | Intention to treat |
| Kras | Kirsten Rat Sarcoma gene |
| LV | Leucovorin |
| MRI | Magnetic resonance imaging |
| NCI CTCAE | National Cancer Institute Common Terminology Criteria for Adverse Events |
| OS | Overall survival |
| PCR | Polymerase chain reaction |
| PD | Progressive disease |
| PK | Pharmacokinetic |
| PFS | Progression-free survival |
| PS | Performance status |
| PR | Partial response |
| RAS | RAS family of genes (Rat sarcoma) |
| RECIST | Response evaluation criteria for solid tumors |
| RO | Resection margin free of tumor |
| SD | Stable disease |
| TEAE | Treatment emergent adverse event |
| TNM | TNM Classification of Malignant Tumours (Tumour, Lymph nodes, metastasis) |